Immu31 is a murine monoclonal antibody (Ab) specific for alpha-fetoprotein
(AFP), a tumor-associated marker. The excellent tumor targeting ability of
Immu31 has led to the development of a Immu31-based radioimmunodiagnostic a
gent, AFP-Scan, for hepatocellular carcinoma and other AFP-producing tumors
. To enhance the capability of Immu31-based immunoconjugates being used in
diagnostic and therapeutic procedures in humans, a humanized version of Imm
u31 (hImmu31) was constructed by grafting the complementarity determining r
egions (CDRs) of murine variable domains for the heavy (VH) and kappa (V ka
ppa) chain to the respective human VH and V kappa framework regions (FRs).
The cDNA encoding the VH and V kappa of Immu31 was cloned by reverse transc
ription-PCR from hybridoma cells, and a chimeric Immu31 (cImmu31) composed
of murine V and human C domains was constructed. Competitive ELISA assays s
howed identical AFP binding activity between the chimeric and murine Abs, c
onfirming the authenticity of the cloned V genes. Based on sequence homolog
y, the EU FR1, FR2, and FR3 and the NEWM FR4 were selected as the scaffold
for grafting VH CDRs and REI FRs for V kappa CDRs of Immu31. The amino acid
residues in murine FRs that are considered to be in contact with the CDRs
of the Ab were maintained in the humanized version. hImmu31, thus construct
ed and expressed, showed comparable immunoreactivity in a competitive bindi
ng ELISA assay to that of murine Immu31 and cImmu31. High-level production
was achieved by expressing hImmu31 in a dhfr-based amplifiable system, and
the productivity has exceeded 100 mg/liter in terminal cultures.